TrialThe oncologist2024

A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors.

Farshid Dayyani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.